Cargando…
Novel Population Pharmacokinetic Approach to Explain the Differences between Cystic Fibrosis Patients and Healthy Volunteers via Protein Binding
The pharmacokinetics in patients with cystic fibrosis (CF) has long been thought to differ considerably from that in healthy volunteers. For highly protein bound β-lactams, profound pharmacokinetic differences were observed between comparatively morbid patients with CF and healthy volunteers. These...
Autores principales: | Shah, Nirav R., Bulitta, Jürgen B., Kinzig, Martina, Landersdorfer, Cornelia B., Jiao, Yuanyuan, Sutaria, Dhruvitkumar S., Tao, Xun, Höhl, Rainer, Holzgrabe, Ulrike, Kees, Frieder, Stephan, Ulrich, Sörgel, Fritz |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630667/ https://www.ncbi.nlm.nih.gov/pubmed/31216743 http://dx.doi.org/10.3390/pharmaceutics11060286 |
Ejemplares similares
-
Comparable Bioavailability and Disposition of Pefloxacin in Patients with Cystic Fibrosis and Healthy Volunteers Assessed via Population Pharmacokinetics
por: Bulitta, Jürgen B., et al.
Publicado: (2019) -
The pharmacokinetics of intranasal droperidol in volunteers characterised via population modelling
por: Cooper, Isabelle, et al.
Publicado: (2018) -
Continuous vs bolus administration of imipenem in critically ill patients with ICU-acquired pneumonia
por: Sakka, S, et al.
Publicado: (2004) -
Comparability of Biosimilar Filgrastim with Originator Filgrastim: Protein Characterization, Pharmacodynamics, and Pharmacokinetics
por: Sörgel, Fritz, et al.
Publicado: (2015) -
Tissue pharmacokinetics of individual macrolides support observed differences in development of bacterial resistance
por: Krasniqi, Shaip, et al.
Publicado: (2010)